Skip to content
Study details
Enrolling now

Atorvastatin Postpartum and Reduction of Cardiovascular Risk

Ohio State University
NCT IDNCT06632379ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

76

Study length

about 1.2 years

Ages

20–50

Sex

Female only

Locations

1 site in OH

What this study is about

This trial is testing whether atorvastatin, a medication, reduces cardiovascular risk in postpartum women with hypertensive disorders of pregnancy. Women will be randomly assigned to either atorvastatin 10mg or a placebo after breastfeeding stops for three months.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Atorvastatin 10 mg
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

atorvastatin (Statin; inhibits HMG-CoA reductase to lower cholesterol)

Drug routes

oral

Endpoints

Secondary: Estimated glomerular filtration rate, Fasting glucose, High-sensitivity C-reactive protein (Hs-CRP) level, Systolic blood pressure, Waist circumference

Body systems

Reproductive Health, Cardiology / Heart